1. [1] Garofalo A, Goossens L, Lemoine A, Ravez S, Six P, Howsam M, et al. [4-(6, 7-disubstituted quinazolin-4-ylamino) phenyl] carbamic acid esters: A novel series of dual egfr/vegfr-2 tyrosine kinase inhibitors. Med Chem Comm 2011; 2: 65-72. [DOI:10.1039/C0MD00183J]

2. [2] Zhang HQ, Gong FH, Ye JQ, Zhang C, Yue XH, Li CG, et al. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual tk inhibitors of egfr and vegfr-2. Eur J Med Chem 2017; 125: 245-254. [DOI:10.1016/j.ejmech.2016.09.039] [PMID]

3. [3] Ahmadzadeh M, Farshdari F, Nematollahi L, Maleknia S, Mohit E. Optimization of her2-based and cell-based elisa for detection of trastuzumab biosimilar. Koomesh 2020; 22: 341-350. (Persian). [DOI:10.29252/koomesh.22.2.341]

4. [4] Osmani F, Rasekhi A, Hajizadeh E, Akbari M E. Simultaneous modeling of multiple recurrences in breast cancer patients. Koomesh 2020; 22: 359-364. (Persian). [DOI:10.29252/koomesh.22.2.359]

5. [5] Yu H, Li Y, Ge Y, Song Z, Wang C, Huang S, et al. Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent egfr inhibitors with enhanced activity against nsclc cell lines. Eur J Med Chem 2016; 110: 195-203. [DOI:10.1016/j.ejmech.2016.01.045] [PMID]

6. [6] Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer 2003; 2: 246-251. [DOI:10.3816/CCC.2003.n.006] [PMID]

7. [7] Chandregowda V, Kush A, Reddy GC. Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives. Eur J Med Chem 2009; 44: 3046-3055. [DOI:10.1016/j.ejmech.2008.07.023] [PMID]

8. [8] Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, et al. Novel 4-anilinoquinazolines with c-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, vegf receptor tyrosine kinase inhibitors. Eur J Med Chem 2002; 45: 1300-1312. [DOI:10.1021/jm011022e] [PMID]

9. [9] Hansch C, Hoekman D, Gao H. Comparative qsar: Toward a deeper understanding of chemicobiological interactions. Chem Rev 1996; 96: 1045-1076. [DOI:10.1021/cr9400976] [PMID]

10. [10] Shayanfar A, Ghasemi S, Soltani S, Asadpour-Zeynali K, J Doerksen R, Jouyban A. Quantitative structure-activity relationships of imidazole-containing farnesyltransferase inhibitors using different chemometric methods. Med Chem 2013; 9: 434-448. [DOI:10.2174/1573406411309030014] [PMID]

11. [11] Verma J, Khedkar VM, Coutinho EC. 3d-qsar in drug design-a review. Current topics in medicinal chemistry 2010; 10: 95-115. [DOI:10.2174/156802610790232260] [PMID]

12. [12] Kharkar PS. Two-dimensional (2d) in silico models for absorption, distribution, metabolism, excretion and toxicity (adme/t) in drug discovery. Current topics in medicinal chemistry 2010; 10: 116-126. [DOI:10.2174/156802610790232224] [PMID]

13. [13] Vapnik V. The nature of statistical learning theory: Springer science & business media; 2013.

14. [14] Shahlaei M, Fassihi A, Saghaie L. Application of pc-ann and pc-ls-svm in qsar of ccr1 antagonist compounds: A comparative study. Eur J Med Chem 2010; 45: 1572-1582. [DOI:10.1016/j.ejmech.2009.12.066] [PMID]

15. [15] Cheng Z, Zhang Y, Fu W. Qsar study of carboxylic acid derivatives as hiv-1 integrase inhibitors. Eur J Med Chem 2010; 45: 3970-3980. [DOI:10.1016/j.ejmech.2010.05.052] [PMID]

16. [16] Darnag R, Mazouz EM, Schmitzer A, Villemin D, Jarid A, Cherqaoui D. Support vector machines: Development of qsar models for predicting anti-hiv-1 activity of tibo derivatives. Eur J Med Chem 2010; 45: 1590-1597. [DOI:10.1016/j.ejmech.2010.01.002] [PMID]

17. [17] Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HD, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure−activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (pd 153035), a potent inhibitor of the epidermal growth factor receptor. Eur J Med Chem 1996; 39: 267-276. [DOI:10.1021/jm9503613] [PMID]

18. [18] Palmer BD, Trumpp-Kallmeyer S, Fry DW, Nelson JM, Showalter HD, Denny WA. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors:  Synthesis, biological evaluation, and modeling of the mode of binding. Eur J Med Chem 1997; 40: 1519-1529. [DOI:10.1021/jm960789h] [PMID]

19. [19] Rewcastle GW, Denny WA, Bridges AJ, Zhou H, Cody DR, McMichael A, et al. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. Eur J Med Chem 1995; 38: 3482-3487. [DOI:10.1021/jm00018a008] [PMID]

20. [20] Rewcastle GW, Palmer BD, Bridges AJ, Showalter HD, Sun L, Nelson J, et al. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as atp site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Eur J Med Chem 1996; 39: 918-928. [DOI:10.1021/jm950692f] [PMID]

21. [21] Teppen BJ. Hyperchem, release 2: Molecular modeling for the personal computer. J Chem Inform Comput Sci 1992; 32: 757-759. [DOI:10.1021/ci00010a025]

22. [22] Mauri A, Consonni V, Pavan M, Todeschini R. Dragon software: An easy approach to molecular descriptor calculations. Match 2006; 56: 237-248.

23. [23] Ghanbarzadeh S, Ghasemi S, Shayanfar A, Ebrahimi-Najafabadi H. 2d-qsar study of some 2, 5-diaminobenzophenone farnesyltransferase inhibitors by different chemometric methods. EXCLI J 2015; 14: 484.

24. [24] Nunes CA, Freitas MP. Aug-mia-qspr on the modeling of sweetness values of disaccharide derivatives. LWT Food Sci Technol 2013; 51: 405-408. [DOI:10.1016/j.lwt.2012.11.019]

25. [25] Habibi-Yangjeh A. Qsar study of the 5-ht 1a receptor affinities of arylpiperazines using a genetic algorithm-artificial neural network model. Monatsh Chem 2009; 140: 523-530. [DOI:10.1007/s00706-008-0084-4]

26. [26] Leardi R, Seasholtz MB, Pell RJ. Variable selection for multivariate calibration using a genetic algorithm: Prediction of additive concentrations in polymer films from fourier transform-infrared spectral data. Anal Chim Acta 2002; 461: 189-200. [DOI:10.1016/S0003-2670(02)00272-6]

27. [27] Soltani S, Abolhasani H, Zarghi A, Jouyban A. Qsar analysis of diaryl cox-2 inhibitors: Comparison of feature selection and train-test data selection methods. Eur J Med Chem 2010; 45: 2753-2760. [DOI:10.1016/j.ejmech.2010.02.055] [PMID]

28. [28] Dastmalchi S, Hamzeh-Mivehroud M, Ghafourian T, Hamzeiy H. Molecular modeling of histamine h3 receptor and qsar studies on arylbenzofuran derived h3 antagonists. J Mol Graph Model 2008; 26: 834-844. [DOI:10.1016/j.jmgm.2007.05.002] [PMID]

29. [29] Jalali-Heravi M, Asadollahi-Baboli M, Shahbazikhah P. Qsar study of heparanase inhibitors activity using artificial neural networks and levenberg-marquardt algorithm. Eur J Med Chem 2008; 43: 548-556. [DOI:10.1016/j.ejmech.2007.04.014] [PMID]

30. [30] Ghandadi M, Shayanfar A, Hamzeh-Mivehroud M, Jouyban A. Quantitative structure activity relationship and docking studies of imidazole-based derivatives as p-glycoprotein inhibitors. Med Chem Res 2014; 23: 4700-4712. [DOI:10.1007/s00044-014-1029-6]

31. [31] Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Model 2002; 20: 269-276. [DOI:10.1016/S1093-3263(01)00123-1]

32. [32] Roy PP, Roy K. On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 2008; 27: 302-313. [DOI:10.1002/qsar.200710043]

33. [33] Moghadam FA, Evazalipour M, Kefayati H, Ghasemi S. 6, 7-disubstituted-4-anilinoquinazoline: Design, synthesis and anticancer activity as a novel series of potent anticancer agents. Pharm Sci 2021; 27: 209-218. [DOI:10.34172/PS.2020.72]

34. [34] Caballero J, Fernández M, Saavedra M, González-Nilo F D. 2d autocorrelation, comfa, and comsia modeling of protein tyrosine kinases' inhibition by substituted pyrido [2, 3-d] pyrimidine derivatives. Bioorg Med Chem 2008; 16: 810-821. [DOI:10.1016/j.bmc.2007.10.024] [PMID]

35. [35] Gozalbes R, Doucet J, Derouin F. Application of topological descriptors in qsar and drug design: History and new trends. Curr Drug Targets Infect Disord 2002; 2: 93-102. [DOI:10.2174/1568005024605909] [PMID]

36. [36] Khan AU. Descriptors and their selection methods in qsar analysis: Paradigm for drug design. Drug Discov Today 2016; 21: 1291-302. [DOI:10.1016/j.drudis.2016.06.013] [PMID]

37. [37] Seedher N, Bhatia S, Singh B. Quantitative correlation between theoretical molecular descriptors and drug-hsa binding affinities for various cox-2 inhibitors. Chem Biol Drug Des 2008; 72: 297-302. [DOI:10.1111/j.1747-0285.2008.00711.x] [PMID]

38. [38] Gosav S, Praisler M, Dorohoi D. Ann expert system screening for illicit amphetamines using molecular descriptors. J Mol Struct 2007; 834: 188-194. [DOI:10.1016/j.molstruc.2006.12.059]

39. [39] Devinyak O, Havrylyuk D, Lesyk R. 3d-morse descriptors explained. J Mol Graph Model 2014; 54: 194-203. [DOI:10.1016/j.jmgm.2014.10.006] [PMID]

40. [40] Gramatica P, Corradi M, Consonni V. Modelling and prediction of soil sorption coefficients of non-ionic organic pesticides by molecular descriptors. Chemosphere 2000; 41: 763-777. [DOI:10.1016/S0045-6535(99)00463-4]

41. [41] Gramatica P. Whim descriptors of shape. QSAR Comb Sci 2006; 25: 327-332. [DOI:10.1002/qsar.200510159]

42. [42] D'Archivio AA, Maggi MA, Mazzeo P, Ruggieri F. Quantitative structure-retention relationships of pesticides in reversed-phase high-performance liquid chromatography based on whim and getaway molecular descriptors. Anal Chim Acta 2008; 628: 162-172. [DOI:10.1016/j.aca.2008.09.018] [PMID]

43. [43] González MP, Terán C, Teijeira M, Helguera AM. Radial distribution function descriptors: An alternative for predicting a2 a adenosine receptors agonists. Eur J Med Chem 2006; 41: 56-62. [DOI:10.1016/j.ejmech.2005.08.004] [PMID]